Omeza Announces Closing of $8.5 Million Series a Financing Co-Led by Astanor and Blukap Ventures, With Participation From Catalyst Investments

Omeza宣布完成850万美元A轮融资，由Astanor和Blukap Ventures共同领投，Catalyst Investments参投。

Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform

围绕这些职位，Omeza 将加速其FDA认证的再生伤口护理平台的临床开发，并在全国范围内扩大商业化规模。

SARASOTA, Fla., April 21, 2026-- Omeza Holdings, Inc. ('Omeza'), a commercial-stage advanced wound care company with an FDA-cleared regenerative product already marketed in the U.S., today announced the closing of an $8.5 million Series A financing round co-led by Astanor and BluKap Ventures, with participation from Catalyst Investments and historical investors including the Florida Opportunity Fund..

佛罗里达州萨拉索塔，2026年4月21日——Omeza Holdings, Inc.（“Omeza”），一家已在美国市场推出FDA认证再生产品的商业阶段高级伤口护理公司，今日宣布完成了由Astanor和BluKap Ventures共同领投、Catalyst Investments及包括佛罗里达机会基金在内的历史投资者参与的850万美元A轮融资。

Omeza is already generating revenue through a nationwide commercial partnership and is advancing clinical programs to expand reimbursement across major hard-to-heal wounds. The round reflects growing institutional conviction in Omeza's differentiated clinical and commercial platform.

Omeza已通过全国性的商业合作伙伴关系产生收入，并正在推进临床项目，以扩大对主要难愈合伤口的报销范围。此轮融资反映了机构对Omeza差异化临床和商业平台的信心不断增强。

Proceeds will be used to accelerate clinical trials, expand commercial capabilities, and strengthen the company's clinical and real-world evidence base to support broader reimbursement coverage.

收益将用于加速临床试验，扩大商业能力，并加强公司的临床和真实世界证据基础，以支持更广泛的报销覆盖。

Advanced wound care represents a multi-billion-dollar market in the United States alone, with significant unmet need for cost-effective, scalable therapies.

先进的伤口护理仅在美国就代表着一个价值数十亿美元的市场，对于具有成本效益、可扩展的疗法存在着显著的未满足需求。

Board appointments

董事会任命

Concurrent with the closing, Omeza's Board of Directors has been strengthened with the appointment of:

与收盘同时，Omeza的董事会通过任命以下人员得到了加强：

Henry Gazay

亨利·加扎伊

Co-founder & Managing Partner

联合创始人兼管理合伙人

BluKap Ventures

蓝卡普创投

Non-executive Director

非执行董事

Edouard Cukierman

爱德华·库基尔曼

Founder & Managing Partner

创始人兼管理合伙人

Catalyst Investments

催化剂投资

Non-executive Director

非执行董事

Eric Archambeau

埃里克·阿查姆博

Founder and Managing Partner

创始人兼管理合伙人

Astanor

阿斯塔诺尔

Board Observer

董事会观察员

These appointments reflect the company's transition toward institutional governance and its next phase of growth. Henry Gazay brings over 30 years of entrepreneurial and investment experience in South Florida and an extensive international network across the Americas, Europe and Asia in healthcare and life sciences.

这些任命反映了公司向制度化治理及其下一阶段增长的过渡。亨利·加扎伊在南佛罗里达州拥有超过30年的创业和投资经验，并在美洲、欧洲和亚洲的医疗保健和生命科学领域拥有广泛的国际网络。

Edouard Cukierman brings over 30 years of cross-border investment expertise spanning the Middle East, Europe, the United States, and Asia, and a proven track record of building governance structures for high-growth technology and life science companies. Astanor will be represented as a Board Observer..

爱德华·库基尔曼拥有超过30年的跨境投资经验，涉足中东、欧洲、美国和亚洲，并在为高增长的技术和生命科学公司建立治理结构方面有着良好的记录。Astanor将以董事会观察员的身份参与。

Company and Product

公司与产品

Omeza's lead product, OCM™, is an FDA-cleared drug-device wound matrix derived from marine lipids and cold water fish peptides. Applied in various settings, it reduces inflammation, disrupts bacterial biofilm, and supports tissue regeneration, offering a highly effective and cost-efficient alternative to traditional skin grafts..

Omeza的主打产品OCM™是一种经FDA批准的药物-设备复合型伤口基质，源自海洋脂质和冷水鱼类肽。它在多种环境下应用，能够减轻炎症、破坏细菌生物膜并促进组织再生，为传统皮肤移植提供了一种高效且经济实惠的替代方案。

Leadership and Investor Commentary

领导层和投资者评论

'This financing marks a pivotal milestone for Omeza as we advance our clinical development and accelerate our commercial strategy. The caliber and diversity of our Board underscore the strength of the investor syndicate we have assembled. Henry contributes deep global healthcare investor relationships and strategic perspective, Edouard brings a proven track record of scaling technology and life science companies across multiple markets, and Eric's role as board observer adds the insight of one of Europe's leading impact investors.

“这次融资标志着Omeza迈出了关键的里程碑，推动了我们的临床开发并加速了我们的商业战略。我们董事会的素质和多样性彰显了我们所组建的投资者集团的实力。Henry带来了深厚的全球医疗保健投资者关系和战略视角，Edouard在多个市场扩展技术与生命科学公司方面有着可靠的成功记录，而Eric作为董事会观察员的角色则增添了欧洲领先的影响投资者之一的洞察力。”

Collectively, this positions Omeza with exceptional strength and clarity as we enter our next phase of growth..

总体而言，这使得Omeza在进入下一个增长阶段时具备了非凡的实力和清晰的方向。

I would like to personally thank one of Omeza's founding Board Directors, Alan George 'A.G.' Lafley, for his outstanding service. A.G. Lafley is an American business leader, who served twice, as Procter & Gamble's CEO, eventually retiring in 2016. As CEO, Lafley was called 'one of the most lauded CEOs in history'.

我要亲自感谢欧米扎公司的一位创始董事会董事，艾伦·乔治（A.G.）拉弗利，他做出了卓越的贡献。A.G. 拉弗利是一位美国商业领袖，曾两度担任宝洁公司首席执行官，最终于2016年退休。作为首席执行官，拉弗利被誉为“历史上最受赞誉的首席执行官之一”。

A.G. is also known as an expert in CEO succession, executive leadership development, and coaching experienced, new, and potential CEOs. His commitment to Omeza and his mentorship while working through the complexities of a start up company, have been invaluable. A.G. will retire from Omeza's Board, and remains a significant shareholder in Omeza.

A.G.还被认为是CEO继任、高管领导力发展以及为有经验的、新任和潜在CEO提供指导方面的专家。他对Omeza的投入以及在初创公司复杂环境中提供的指导，具有不可估量的价值。A.G.将从Omeza董事会退休，但仍然是Omeza的重要股东。

We wish him well.'.

我们祝他一切顺利。

- Cynthia Flowers, Chief Executive Officer, Omeza

辛西娅·弗劳尔斯，首席执行官，奥梅扎

'Omeza combines compelling clinical validation with a scalable commercial model addressing a large and underserved market. Its use of sustainably sourced, marine-derived biological compounds positions the company at the forefront of a new generation of regenerative wound care solutions. This strategy aligns closely with BluKap's focus on translating ocean biodiversity into next-generation therapeutics.

Omeza 将引人注目的临床验证与可扩展的商业模式相结合，针对一个庞大且服务不足的市场。其使用可持续来源的海洋生物化合物，使公司处于新一代再生伤口护理解决方案的前沿。这一战略与 BluKap 致力于将海洋生物多样性转化为下一代治疗手段的重点高度契合。

We are proud to lead this round alongside Astanor, Catalyst, and our co-investors, and to partner with Cynthia and the Omeza team as they scale a truly differentiated platform.'.

我们很自豪能与Astanor、Catalyst以及我们的共同投资者一起领导这一轮投资，并与Cynthia和Omeza团队合作，扩大一个真正差异化的平台。

- Henry Gazay, Co-founder & Managing Partner, BluKap Ventures

- 亨利·加扎伊，联合创始人兼管理合伙人，BluKap Ventures

'Omeza strongly aligns with Astanor's investment thesis at the intersection of technology and nature, and our focus on nature-based solutions for human health. The company's use of sustainably sourced, marine-derived biological compounds in efficient wound care addresses the significant burden of chronic non-healing wounds, a condition that affects millions of patients, particularly older adults and those living with diabetes or vascular disease.

“Omeza 与 Astanor 在技术和自然交叉领域的投资理念高度契合，我们专注于基于自然的解决方案以改善人类健康。该公司利用可持续来源的海洋生物化合物进行高效伤口护理，解决了慢性不愈合伤口带来的重大负担，这种状况影响着数百万患者，尤其是老年人以及糖尿病或血管疾病患者。”

This aligns directly with our impact thesis and our Article 9 commitment to investments that deliver measurable planetary and human health outcomes. We look forward to supporting Omeza's growth as it advances its clinical programs and builds a lasting platform in regenerative medicine.'.

这与我们的影响论题和第九条承诺直接一致，即投资于可衡量的行星和人类健康成果。我们期待支持Omeza的成长，因为它推进其临床项目并在再生医学领域建立一个持久的平台。

-Eric Archambeau, Founder & Senior Managing Partner, Astanor

-Eric Archambeau，创始人兼高级管理合伙人，Astanor

'Omeza exemplifies the kind of innovative, clinically grounded company that Catalyst seeks to support, one that combines a clear market need with a differentiated scientific approach and a strong management team. I am delighted to join the Board and to contribute to Omeza's growth through Catalyst's global network and cross-border investment expertise.'.

“Omeza 展现了 Catalyst 希望支持的那种创新且以临床为基础的公司，它结合了明确的市场需求、差异化的科学方法以及强大的管理团队。我很高兴加入董事会，并通过 Catalyst 的全球网络和跨境投资专长为 Omeza 的成长做出贡献。”

- Edouard Cukierman, Founder & Managing Partner, Catalyst Investments

- 爱德华·库基尔曼，创始人兼管理合伙人，催化剂投资

The Series A follows a broader effort to streamline Omeza's capitalization table, align its investor base, and strengthen governance ahead of future institutional financing.

A轮融资之前，Omeza进行了更广泛的努力，以简化其资本化表，调整投资者基础，并在未来的机构融资之前加强治理。

The transaction also reflects the continued emergence of South Florida as a growing hub for life sciences and MedTech innovation, supported by a rapidly expanding ecosystem of investors, operators, and healthcare institutions.

这笔交易还反映了南佛罗里达作为生命科学和医疗技术创新增长中心的持续崛起，这一趋势得到了不断扩大的投资者、运营商和医疗机构生态系统的支持。

ABOUT OMEZA

关于OMEGA

Omeza Holdings, Inc. is a U.S.-based advanced wound care company developing and commercializing marine-derived collagen and lipid products, with an FDA-cleared product already on the market and ongoing clinical programs to expand reimbursement and indications. Its lead product, OCM, incorporates sustainably sourced marine-derived biological compounds, including fish collagen, to accelerate healing in complex wounds, addressing a significant unmet medical need in the U.S.

欧米扎控股公司（Omeza Holdings, Inc.）是一家总部位于美国的先进伤口护理公司，致力于开发和商业化海洋源胶原蛋白和脂质产品。该公司已有经FDA批准的产品上市，并正在进行临床项目以扩大报销范围和适应症。其主打产品OCM结合了可持续来源的海洋生物化合物，包括鱼胶原蛋白，用以加速复杂伤口的愈合，满足了美国一项重要的未满足医疗需求。

healthcare system. For more information, visit www.omeza.com..

医疗保健系统。欲了解更多信息，请访问 www.omeza.com。

ABOUT BLUKAP VENTURES

关于BLUKAP风险投资公司

BluKap Ventures is a global venture capital firm focused exclusively on ocean biotechnology. The firm backs companies developing next-generation therapeutics and technologies derived from ocean biodiversity, with a clear mission to unlock the medical value of sustainably sourced marine compounds. At the crossroads of human health and the blue economy, BluKap advances innovations that convert marine science into scalable, high-impact healthcare solutions.

BluKap Ventures 是一家专注于海洋生物技术的全球风险投资公司。该公司支持开发下一代源自海洋生物多样性的治疗药物和技术的企业，其明确使命是释放可持续来源海洋化合物的医学价值。在人类健康与蓝色经济的交汇点上，BluKap 推动将海洋科学转化为可扩展、高影响力的医疗保健解决方案的创新。

Founded by Henry Gazay and Jean-François Trecco, BluKap combines deep entrepreneurial and investment experience with a strong transatlantic network across healthcare, biotechnology, and marine science ecosystems. The firm provides portfolio companies with capital, strategic guidance, and access to a global network of investors, industry partners, and scientific experts.

由亨利·加扎伊和让-弗朗索瓦·特雷科创立的布鲁卡普（BluKap）结合了深厚的创业和投资经验，以及横跨医疗保健、生物技术和海洋科学领域的强大跨大西洋网络。该公司为旗下投资组合公司提供资金、战略指导，并连接全球投资者、行业合作伙伴和科学专家的网络。

For more information, visit www.BluKap.vc..

欲了解更多信息，请访问 www.BluKap.vc。

ABOUT ASTANOR

关于ASTANOR

Astanor is a global impact investment firm with $1B in assets under management, backing seed through growth stage companies at the intersection of healthspan, nature, and physical AI. Founded in 2017, Astanor counts circa 50 investments to date in Europe, North America and beyond. The firm partners with visionary entrepreneurs and management teams building scalable solutions across agriculture, food production, and healthcare, applying robotics, AI, and nature-based science to advance human and planetary health.

Astanor是一家全球影响力投资公司，管理着10亿美元的资产，支持处于健康寿命、自然和物理人工智能交叉领域的种子期到成长期公司。自2017年成立以来，Astanor已在欧洲、北美及其他地区进行了约50项投资。该公司与富有远见的企业家和管理团队合作，构建横跨农业、食品生产和医疗保健的可扩展解决方案，应用机器人技术、人工智能和基于自然的科学来促进人类和地球的健康。

More information is available at www.astanor.com..

更多信息请访问 www.astanor.com。

ABOUT CATALYST INVESTMENTS

关于催化剂投资

Catalyst Investments is an Israel-based private equity multi-fund firm with over 25 years of experience investing in high-growth technology and life science companies. Founded by Edouard Cukierman, Catalyst focuses on disruptive, internationally scalable companies with an Israel nexus across sectors including enterprise SaaS, cybersecurity, life sciences, climate tech, and smart mobility.

Catalyst Investments是一家总部位于以色列的私募股权多基金公司，拥有超过25年投资高增长技术和生命科学公司的经验。该公司由埃杜尔·库基尔曼（Edouard Cukierman）创立，专注于具有颠覆性、国际可扩展性且与以色列相关的公司，涵盖企业SaaS、网络安全、生命科学、气候技术以及智能移动等多个领域。

The firm leverages a global network spanning the United States, Europe, Asia, and emerging markets to support portfolio companies with capital, strategic guidance, and cross-border expansion. Cukierman & Co. Investment House, the affiliated investment bank, has been engaged in over $10.8 billion of corporate finance transactions since its establishment in 1993.

该公司利用覆盖美国、欧洲、亚洲和新兴市场的全球网络，为投资组合公司提供资本、战略指导和跨境扩张支持。自1993年成立以来，其附属投资银行Cukierman & Co. Investment House已参与了超过108亿美元的企业融资交易。

For more information, visit www.catalyst-fund.com..

欲了解更多信息，请访问 www.catalyst-fund.com。

Forward-looking statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Omeza's clinical development programs, commercial strategy, future financing activities, and market opportunity. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: the outcome of ongoing and planned clinical trials; regulatory review and approval timelines by the U.S.

本新闻稿包含1995年《私人证券诉讼改革法》意义上的前瞻性声明，包括与Omeza的临床开发计划、商业战略、未来融资活动和市场机会相关的声明。这些声明受风险和不确定性的影响，可能导致实际结果大相径庭，包括但不限于：正在进行和计划中的临床试验的结果；美国监管机构的审查和批准时间表。

Food and Drug Administration; the availability of reimbursement from government and private payers; the company's ability to raise additional capital on acceptable terms or at all; competitive developments in the wound care and regenerative medicine markets; and broader macroeconomic and market conditions.

食品和药物管理局；政府和私人支付方的报销可用性；公司以可接受的条件或完全筹集额外资本的能力；伤口护理和再生医学市场的竞争发展；以及更广泛的宏观经济和市场状况。

These forward-looking statements speak only as of the date of this release. Omeza undertakes no obligation to update or revise any forward-looking statements except as required by applicable law..

这些前瞻性声明仅截至本发布日期有效。除非适用法律要求，Omeza不承担更新或修改任何前瞻性声明的义务。

Contact:

联系人：

Media contact

媒体联系人

Cynthia Flowers- CEO Omeza Holdings

辛西娅·弗劳尔斯 - Omeza Holdings首席执行官

cflowers@omeza.com

cflowers@omeza.com

Henry Gazay - Co-founder BluKap ventures

亨利·加扎伊 - 蓝卡普风险投资公司联合创始人

hgazay@blukap.vc

hgazay@blukap.vc